Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ALX Oncology Holdings ( (ALXO) ) has shared an update.
On April 13, 2026, ALX Oncology appointed veteran biopharmaceutical executive Jeff Knight as Chief Development and Operating Officer, underscoring its push into a more advanced growth phase. Knight, who brings more than 30 years of experience in clinical development, regulatory affairs and operations from roles at Crinetics, Poseida, Halozyme, Amgen, Onyx and Genentech, will oversee development and operations as the company navigates late-stage clinical execution.
Under an employment offer letter, Knight will receive a $565,000 annual base salary, a target bonus equal to 40% of base pay and stock options for 800,000 shares that vest over four years, aligning his incentives with long-term shareholder value. His appointment, backed by standard change-of-control, severance and indemnification agreements, is intended to strengthen ALX Oncology’s operational infrastructure as it approaches key milestones in its evorpacept and ALX2004 programs over the next 12 to 18 months.
The most recent analyst rating on (ALXO) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on ALX Oncology Holdings stock, see the ALXO Stock Forecast page.
Spark’s Take on ALXO Stock
According to Spark, TipRanks’ AI Analyst, ALXO is a Neutral.
The score is held back primarily by weak financial fundamentals (no revenue, ongoing losses and cash burn, and a diminished equity base) and bearish technicals (price below key moving averages with negative MACD). Offsetting these, the latest earnings call was relatively strong due to the major financing extending runway through 2028 and encouraging biomarker-driven clinical signals with defined upcoming milestones; valuation metrics provide limited insight given the negative P/E and no dividend.
To see Spark’s full report on ALXO stock, click here.
More about ALX Oncology Holdings
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company focused on developing novel cancer therapies to extend patients’ lives. Its lead candidate, evorpacept, is being tested in multiple trials across a range of tumor types as a potential cornerstone immuno-oncology therapy, while its second program, ALX2004, is an EGFR-targeted antibody-drug conjugate in an ongoing Phase 1 trial for EGFR-expressing solid tumors.
Based in South San Francisco and listed on Nasdaq under the ticker ALXO, the company is positioning its pipeline to address significant unmet needs in oncology. By advancing differentiated biologic candidates through early and late-stage clinical development, ALX Oncology aims to build a scalable platform in immuno-oncology and solid tumor therapeutics.
Average Trading Volume: 808,476
Technical Sentiment Signal: Sell
Current Market Cap: $223.7M
For an in-depth examination of ALXO stock, go to TipRanks’ Overview page.